Insights Into Acute Lymphoblastic Leukemia (ALL)
Perspectives on current treatment practices regarding adult and AYA ALL, the role of MRD, and current treatment practices in relapsed/refractory disease
Faculty Chair
Elias Jabbour, MD
The University of Texas, MD Anderson Cancer Center, Houston, TX
Faculty Chair
Elias Jabbour, MD
The University of Texas, MD Anderson Cancer Center, Houston, TX
Faculty Chair
Elias Jabbour, MD
The University of Texas, MD Anderson Cancer Center, Houston, TX
Faculty Chair
Elias Jabbour, MD
The University of Texas, MD Anderson Cancer Center, Houston, TX
Faculty Chair
Elias Jabbour, MD
The University of Texas, MD Anderson Cancer Center, Houston, TX
Faculty Chair
Elias Jabbour, MD
The University of Texas, MD Anderson Cancer Center, Houston, TX
More Information
- Virtual Series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual Series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual Series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More information
- Virtual Series
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Virtual Series
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
More Information
- Virtual Series
- California, Nevada
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of acute lymphoblastic leukemia (ALL)
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: blinatumomab, ponatinib, inotuzumab ozogamicin, liposomal vincristine, and chimeric antigen receptor (CAR) T-cell therapy
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors will comprise 10–15 medical oncologists representative of each region
